Roth Capital Reiterates Buy on Ligand Pharma (LGND) Following E.U. Approval of Promacta
Tweet Send to a Friend
Roth Capital reiterated a Buy rating and $135.00 price target on Ligand Pharma (NASDAQ: LGND) following the E.U. approval of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
